July 11, 2019
Telehealth and mail-order health and wellness consumer brands Hims & Hers have been joined by Dr. Pat Carroll. Formerly a chief medical officer at Walgreens and a 20,000-patient primary care group, Carroll take on a similar role for the growing startup.
“Our vision is an ecosystem where people have plenty of options to get the care that’s right for them. Depending on what they need, that...
May 20, 2019
MyHeritage, an Israeli company that has been doing ancestry-related genetic testing since 2016, has announced a new product that brings the company into the health-focused consumer DNA testing space alongside the likes of 23andMe.
MyHeritage DNA Health+Ancestry is a single test that includes a wide-range of genetic aptitudes for possible health conditions: specifically, the company will offer 11...
23andMe kits at a Beverly Hills event in 2017. Credit: Matt Winkelmeyer, Getty Images
April 29, 2019
This morning 23andMe announced that it is teaming up with The Michael J. Fox Foundation for Parkinson’s Research on a new data and analytics platform dedicated to Parkinson’s research.
The new tool, dubbed Fox Insight Data Exploration Network (Fox DEN) is set to include patient surveys, de-identified genetic data and data exploration tools all aimed studying Parkinson’s.
Users who opt into the...
March 27, 2019
Direct-to-consumer gene tests like Ancestry.com and 23andMe are increasingly informing consumers about gene alterations that could signal health risks. But those tests look at only a few positions on particular genes, as opposed to medical sequencing that is much more thorough. And, according to a 2018 study by Ambry Genetics in Genetics in Medicine, these results can be wrong — the study showed...
March 11, 2019
At SXSW in Austin this weekend, consumer genomics company 23andMe unveiled its latest test, a predisposition report on Type 2 diabetes.
The test, which has not undergone FDA clearance and does not purport to diagnose a condition, is designed to help people understand when they’re at a higher-than-normal risk for Type 2 diabetes so they can alter their lifestyle. To assist with the latter piece,...
January 24, 2019
Apple versus posionous gas. Patently Apple has spotted a newly published patent application that seems to suggest that miniature sensors for poisonous gas may be a feature of future Apple devices.
Filled in March of 2018, the application’s diagrams include examples of the sensors housed within an enclosure such as an Apple Watch and describe detection capabilities for “at least one of ozone (O....
January 17, 2019
Dr. Bimal Shah and Courtnee Westendorf have been announced as the chief medical officer and chief marketing officer, respectively, of Livongo Health. Shah was promoted internally from a position of SVP of clinical strategy, while Westendorf previously served as the chief marketing officer of the Oakland Raiders football team.
“We are excited to have a leading marketing executive like Courtnee...
January 8, 2019
This morning, consumer genomic giant 23andMe revealed that it is teaming up with Lark Health, an AI platform that helps users manage chronic conditions, on a new initiative that will integrate a user’s 23andMe genetic information into Lark’s Wellness Program and Diabetes Prevention Program. The idea is that Lark’s AI weight loss and wellness coach will be able to access a user’s genetic...
October 31, 2018
Yesterday afternoon the FDA announced that it would permit 23andMe to market its Personal Genome Service Pharmacogenetic Reports test. The test offers consumers information on whether they posses one of 33 variants across multiple genes that could impact their body’s ability to metabolize certain medications.
The purpose of this test is to inform patients and encourage them to more thoroughly...
September 11, 2018
The Cadillac of gene tests? 23andMe is considering a $749 premium gene test offering, considerably more expensive than the $99 to $199 products the company has offered thus far, CNBC reports. Some users received email notifications about a premium service at that price, but clicking the link did nothing. According to 23andMe, it’s only testing user interest and has no plans for a roll out.